Factors influencing the management of atherothrombotic disease in secondary prevention in the private outpatient cardiology setting: Results of the Prisma survey;Étude sur les facteurs influençant les prescriptions en prévention secondaire de la maladie athérothrombotique en pratique de ville: Résultats de l'étude Prisma

Annales de Cardiologie et d'Angeiologie

Volumn 52, Issue 1, 2003, Pages 20-29

  Cambou, J P ^a   Ferrieres, J ^b   Grenier, O ^c   Boka, G ^d   Cantet, C ^a   Leizorovicz, A ^e  

^a INSERM   (France)

^b Service de Cardiologie   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e HÔPITAL NEUROLOGIQUE   (France)

Author keywords

ACE Inhibitors; Antiplatelet agents; Atherothrombosis; Beta blockers; Ischemic shoke; Myocardial infarction; Peripheral arterial disease; Secondary prevention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; LIPID; PERIPHERAL VASODILATING AGENT; PYRIDINE DERIVATIVE; STATINE DERIVATIVE; THIENO[2,3 B]PYRIDINE DERIVATIVE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BRAIN EMBOLISM; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONSULTATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY CARE UNIT; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FRANCE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBESITY; OUTPATIENT; PRESCRIPTION; PREVALENCE; SECONDARY PREVENTION; SITTING; SMOKING; STROKE; SYMPTOM; THROMBOSIS; AMBULATORY CARE; BRAIN ISCHEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG UTILIZATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; REGISTER; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; AGED; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 0037300150     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3928(02)00179-8     Document Type: Article

References (20)

1. De Velasco JA, Cosin J, Lopez-sendon JL, De Teresa E, De Oya carasco JL, Navarro A. La prevencion secondaria del infarto de miocardio en España: estudio Prevese. Rev Esp Cardiol 1997;50:406-15.
2. Euroaspire I. I.I Group. Clinical reality coronary prevention guideliness: a comparison of euroaspire I and II in nine countries. Lancet 2001;357:995-1001.
3. Bennett KE, Williams D, Feely J. Inequalities in prescribing of secondary prevention therapies for ischaemic heart disease in Ireland. Irish Med J 2002;95:169-72.
4. Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O. Avezum A for the Grace investigators, Management of acute coronary syndromes, Variations in practice and outcome. Eur Heart J 2 2002;3:177-89.
5. Gupta M, Doobay AV, Singh N, Anand SS, Raja F, Mawji F, et al. Risk factors, hopital management and outcomes after myocardial infarction in South Asian Canadian and matched control subjects. Can Med Ass J 2002;166:717-22.
6. Danchin N, Vaur L, Genes N, Renault M, Ferrières J, Etienne S, et al. management of acute myocardial infarction in intensive care units in 1995: a nationwide french survey of practice and early hospital results. J Am Coll Cardiol 1997;30:1505-98.
7. Escoffier S, De Gevigney G, Ecochard R, Rabilloud M, Cao D, Cheneau E, et al. Treatment at discharge after myocardial infarction in 2,102 patients, The Prima study. Acta Cardiol 2001;56:17-26.
8. Grenier O, Cambou JP, Ferrières J, Cantet C, Danchin N. Caractéristiques initiales et prise en charge thérapeutique des sujets jeunes (âge inférieur à 45 ans) hospitalisés pour un syndrome coronaire aigu: résultats des études françaises Prevenir 1 et Prevenir 2. Ann Cardiol Angéiol 2002;51:15-9.
9. Hart RG, Benavente O, Mcbride R, Pearce LA. Antithrombotic therapy to preventstoke in patient withatrial fibrillationa mete analysis. Ann Intern Med 1999;131:492-501.
10. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
11. Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM 2002;95:461-8.
12. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (Cats) in thromboembolic stroke. Lancet 1989;I:1215-20.
13. Teo Koon K, Yusuf S, Pfeffer M, Kober L, Half A, Pogue J, et al., for the ACE inhibitors Collaborative Group. Effect of long term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. The lancet 2002;360:1037-42.
14. Ferrières J, Danchin N, Grenier O, Cantet C, Thomas D, Cambou JP. Optimizing the prescription of statins after an acute coronary syndrome: the influence of coronary angioplasty and total cholesterol level. Cardiovasc Drugs Ther 2001;15:559-60.
15. Danchin N, Grenier O, Ferrières J, Cantet C, Cambou JP. Use of secondary preventive drug in patients with acute coronary syndromes treated medically or with coronary angioplasty: result from the nationwide French Prevenir survey. Heart 2002;88:159-62.
16. CIBIS-2 investigators and committees. The CIBIS-2 study a randomized trial. Lancet 1999;353:9-13.
17. The Capricorn investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the Capricorn randomised trial. Lancet 2001;357:1385-90.
18. Progress Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;339:1349-57.
19. The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
20. Heart Outcome Prevention Evaluation (Hope) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the Hope study and Microhope substudy. Lancet 2000;355:253-9.